Authors
Edith A Perez, Robert G Josse, Kathleen I Pritchard, James N Ingle, Silvana Martino, Brian P Findlay, Tamara N Shenkier, Richard G Tozer, Michael J Palmer, Lois E Shepherd, Shifang Liu, Dongsheng Tu, Paul E Goss
Publication date
2006/8/1
Journal
Journal of Clinical Oncology
Volume
24
Issue
22
Pages
3629-3635
Publisher
American Society of Clinical Oncology
Description
Purpose
Aromatase inhibition depletes estrogen levels and may be associated with accelerated bone resorption. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study MA.17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen.
Patients and Methods
Eligible women had a baseline BMD T score of at least 2.0 in either the hip or L2-4 spine; all received calcium 500 mg and vitamin D 400 U daily. Percentage change in BMD (L2-L4 spine and hip) at 12 and 24 months, rate of osteoporosis, and change in markers of bone formation (serum bone alkaline phosphatase) and resorption (serum C-telopeptide and urine N-telopeptide) at 6, 12, and 24 months were compared.
Results
Two hundred twenty-six …
Total citations
Scholar articles
EA Perez, RG Josse, KI Pritchard, JN Ingle, S Martino… - Journal of Clinical Oncology, 2006